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Abstract
Background: Knee osteoarthritis (OA) is a common and important cause of pain and disability, but interventions
aimed at modifying structures visible on imaging have been disappointing. While OA affects the whole joint,
synovitis and effusion have been recognised as having a role in the pathogenesis of OA. Krill oil reduces knee pain
and systemic inflammation and could be used for targeting inflammatory mechanisms of OA.
Methods/design: We will recruit 260 patients with clinical knee OA, significant knee pain and effusion-
synovitis present on MRI in five Australian cities (Hobart, Melbourne, Sydney, Adelaide and Perth). These
patients will be randomly allocated to the two arms of the study, receiving 2 g/day krill oil or inert placebo
daily for 6 months. MRI of the study knee will be performed at screening and after 6 months. Knee symptoms,
function and MRI structural abnormalities will be assessed using validated methods. Safety data will be
recorded. Primary outcomes are absolute change in knee pain (assessed by visual analog score) and change
in size of knee effusion-synovitis over 24 weeks. Secondary outcomes include improvement in knee pain over
4, 8, 12, 16 and 20 weeks. The primary analyses will be intention-to-treat analyses of primary and secondary
outcomes. Per protocol analyses adjusting for missing data and for treatment compliance will be performed
as the secondary analyses.
Discussion: This study will provide high-quality evidence to assess whether krill oil 2 g/day reduces pain and
effusion-synovitis size in older adults with clinical knee OA and knee effusion-synovitis. If krill oil is effective
and confirmed to be safe, we will provide compelling evidence that krill oil improves pain and function,
changes disease trajectory and slows disease progression in OA. Given the lack of approved therapies for
slowing disease progression in OA, and moderate cost of krill oil, these findings will be readily translated into
clinical practice.
Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12616000726459. Registered on 02
June 2016.
Universal Trial Number (UTN) U1111–1181-7087.
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Background
Osteoarthritis (OA) is a major cause of pain, functional
limitation and disability worldwide [1], with hip and
knee OA ranked as the 11th highest contributor to glo-
bal disability and 38th highest in disability-adjusted life
years (DALYs) [2]. Treatment remains focussed on man-
aging pain, which is ranked by patients as the highest
treatment priority [3]. However, pain control remains
poor in 50% of non-operatively treated patients [4]. Des-
pite the large disease burden, currently no approved dis-
ease modifying OA drugs (DMOADs) are available.
OA is a heterogeneous, complex disease with multiple
phenotypes [5, 6]. Few treatments have been demon-
strated to be effective for OA pain and to slow down
changes in structure, and this may be partly due to treat-
ing everyone as if they have the same pathological
process. Treatment can be optimised by selecting study
populations by subgroups with specific features that are
likely to respond to targeted treatments. One such
phenotype is an inflammatory phenotype.
OA is typically considered a ‘non-inflammatory’ type
of arthritis; however, localised low-grade inflammation
is an important factor in OA pathogenesis, with in-
flammatory patterns observed both early [7] and late
[8] in the disease process. In OA, inflammatory
changes have been demonstrated both systemically
and in the affected joint. Moreover, there is now evi-
dence that inflammation helps distinguish clinically
distinct phenotypes of OA [9].
Elevated levels of systemic inflammation (as observed
by high sensitive C reactive protein (hsCRP) [10] are ob-
served in persons with OA compared to controls, and
are positively correlated with the degree of synovial in-
flammatory infiltration in OA [11]. hsCRP levels are as-
sociated with both symptoms and disease markers, with
higher hsCRP levels associated with greater pain (in both
a meta-analysis [10] and longitudinal data from our
centre [12]), decreased physical function [10], decreased
cartilage volume [13] and disease progression [7, 14].
Therefore, systemic inflammation predicts both pain and
structural outcomes in OA.
Inflammation also occurs locally within joints. Pro-
inflammatory cytokines, including interleukin (IL)-1β,
tumour necrosis factor-α (TNF-α), and IL-6 are pro-
duced by synovium and chondrocytes, and contribute to
the progression of cartilage degradation [8]. Localised in-
flammation presents as effusion (excess synovial fluid
within the joint space) and/or synovitis (thickening of
the synovium); these predict pain [15–18], including
new and worsening pain over 2.6 years [18]. Effusion-
synovitis also predicts structural changes— cartilage de-
fects, bone marrow lesions (BMLs) and increased cartil-
age loss over 2.6 years [19]—and joint replacement [20].
Thus, stopping the cascade of inflammation is likely to
slow down deleterious changes in knee structure and re-
versing inflammation has the potential to improve out-
comes globally in knee OA.
High levels of inflammation in OA can be targeted
with treatments including oral prednisolone [21] or bio-
logics [22], but these therapies are expensive and have
too many side effects for widespread use. Safer treat-
ments for reducing inflammation are needed.
Fish oil is effective in people with rheumatoid arthritis
(RA), reducing pain [23], morning stiffness and number
of painful and/or tender joints [23, 24], and non-
steroidal anti-inflammatory drug (NSAID) consumption
[23, 25]. This is an effective add-on therapy to standard
RA therapies, reducing the risk of treatment failure and
increasing the rate of remission [26]. Efficacy data on
the use of marine-sourced oils is more limited in people
with OA. Observational data suggest that omega-6 and
omega3 polyunsaturated fatty acids from dietary sources
may have beneficial effects on synovitis and cartilage
damage cross-sectionally [27], but that use of a variety of
marine oils is ineffective for OA pain [28, 29], although
there is marked heterogeneity amongst the predomin-
antly poor quality trials [28], and none were enriched for
participants with evidence of an inflammatory pheno-
type. Canola oil/low dose fish oil may be effective [29].
However, unlike marine oils in general, oil from Antarc-
tic krill (Ephausia superba, a zooplankton crustacean)
may be effective in people with OA. Like fish oil, it is
high in eicosapentanoic acids (EPA) and decosahexanoic
acid (DHA) [30], although the chemical structures of the
fatty acids differ (phospholipids, rather than triacylglyc-
erol or fatty acid ethyl esters); but unlike fish oil, it also
naturally contains antioxidants (predominantly astax-
anthin [30]). Additionally, bioavailability of krill oil is
better than fish oil, as comparable amounts of EPA and
DHA are obtained from lower doses of krill oil com-
pared to fish oil [31]. In animal studies, krill oil supple-
mentation had larger effects on most clinical outcomes
than fish oil [32], while krill oil reduced the severity of
inflammatory arthritis in mice by 50% compared to con-
trols [32]. In mice transgenic for human TNF-α, both
fish and krill oil improved plasma cholesterol levels, but
only krill oil had additional beneficial effects on markers
of fatty acid oxidation [33]. Therefore, bioavailability
data and animal studies suggest that krill oil has anti-
inflammatory and anti-oxidative effects and may be a
better treatment in vivo than fish oil.
Two randomised controlled trials (RCTs) including
people with osteoarthritis have demonstrated that daily
krill oil (300 mg [34] or 2 g [35]) is effective in reducing
some aspect of knee pain [34, 35], functional impairment
[34, 35], and stiffness [35]. However, these RCTs have
methodological limitations, including being of short dur-
ation (30 days), having poor documentation of adverse
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events, not including any imaging data to determine the
effect of krill oil on knee structures, and not targeting
patients with evidence of inflammation.
Therefore, we aim to compare, using a randomised,
placebo-controlled double-blind design over 6 months,
the effect of 2 g krill oil daily compared to identical pla-
cebo, on knee pain and MRI-detected knee effusion-
synovitis size (primary outcomes) in participants with
clinical knee OA, significant knee pain and effusion-
synovitis on MR imaging over 24 weeks.
Objective
We are conducting a multi-centre randomised, placebo-
controlled double-blind clinical trial. This will compare
efficacy of krill oil vs identical placebo to treat knee OA
(both pain and structure) in 260 patients with clinical
knee OA, significant knee pain and effusion-synovitis on
imaging.
We hypothesise that krill oil (2 g daily) will decrease
pain (assessed by 100 mm visual analog scale (VAS))
score by 10mm more than identical placebo over 24
weeks and decrease effusion-synovitis size over 24 weeks
(co-primary hypotheses) and improve knee pain over 4,
8, 12, 16, and 20 weeks (secondary hypotheses) in pa-
tients with symptomatic knee OA and knee effusion-
synovitis, compared with placebo. If krill oil proves ef-
fective, it will offer a novel therapeutic approach to re-
duce knee OA progression.
Methods/design
Study design
This randomised trial of krill oil for OA of the knee
(KARAOKE) study is a multicentre, randomised, double-
blind, placebo-controlled superiority trial over 24 weeks.
The trial was registered on the Australian New Zealand
Clinical Trials Registry prior to recruitment, and trial
reporting will be guided by the Consolidated Standards
of Reporting Trials (CONSORT) statement [36]. We aim
to recruit a convenience sample of 260 patients with
clinical knee OA, significant knee pain and effusion-
synovitis visualised on MRI. Patients will be recruited via
the OA Clinical Trial Network, at Australian public hos-
pitals in Melbourne, Sydney, Adelaide and Perth and a
research institute in Hobart, using a combined strategy,
including collaboration with general practitioners, rheu-
matologists and orthopaedic surgeons, as well as adver-
tising through local and social media. Patients will be
encouraged to contact their local research nurse via
email or telephone.
Inclusion criteria
Inclusion criteria are as follows: males and females aged
≥ 40 years; with significant knee pain on most days (de-
fined as a pain score ≥ 40 mm on a 100-mm VAS); and
meeting the American College of Rheumatology (ACR)
criteria for symptomatic knee OA [37], assessed by a
physician, and any effusion-synovitis present on MRI
(defined as grade 1 or more according to modified
WORMS scoring [18, 38]).
Exclusion criteria
Exclusion criteria are as follows:
1. Significant knee injury within the last 6 months
2. Use of anticoagulants, high dose aspirin or NSAIDs,
as krill oil is contraindicated in such people
3. Unwillingness to stop taking krill oil and fish oil
medications 30 days prior to the trial and during
the trial (minimum washout 4 weeks)
4. Other forms of inflammatory arthritis (especially
rheumatoid arthritis and gout)
5. Seafood allergy
6. Arthroscopy or open surgery in the “study” knee in
the last 12 months
7. Injections of corticosteroids (last 3 months) or
hyaluronic acid (last 6 months) in the index knee
8. Women who are pregnant or breastfeeding
9. Use of any investigational drug(s) and/or devices
within 30 days prior to randomisation
10. Presence of any serious medical illness that may
preclude 24-week follow-up
11. Inability to provide informed consent
12. Inability to have an MRI (claustrophobia,
pacemakers, metal in eyes, metal in knees that
disrupt the images at the area of interest)
13. Severe knee OA (joint space narrowing (JSN)) on x-
ray of grade 3 using the Osteoarthritis Research So-
ciety International (OARSI) atlas [39])
Randomisation and blinding
Study participants were allocated to receive either krill
oil or placebo in a 1:1 ratio based on computer-
generated random numbers using a central randomisa-
tion website hosted by the University of Tasmania using
adaptive allocation (minimisation) [40]. Briefly, the ran-
domisation program examined the number of partici-
pants that were currently assigned to each of the two
arms and then adjusted the randomisation thresholds so
that the arm with the fewest participants would have a
greater chance of being selected. Randomisation will be
stratified by study site and is accessible by a dedicated
website. This will be conducted by staff members with
no direct involvement in the study.
The randomised controlled trial will be a double-blind
one, with both patients and investigators assessing out-
comes blinded to treatment allocation. Allocation con-
cealment and double blinding will be ensured by: 1) use
of identical softgels for each group; 2) objective
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measures of knee structural changes being made by
trained observers blinded to group allocation; and 3)
subjective measures being taken by research nurses
blinded to group allocation.
Emergency unblinding will be allowed in limited situa-
tions that impact on the safety of study patients. Code-
break for the full randomisation schedule will be main-
tained by the University of Tasmania. Patients who are
unblinded will be withdrawn from treatment but will
continue to be followed as per the planned follow-up
schedule.
Intervention
Eligible people will receive 2 × 1 g softgels daily of either
krill oil or placebo for 6 months. The krill oil (Superba
Boost product) contains 190 mg/g of EPA and 100mg/g
of DHA. The total omega-3 content is 350 mg/g, total
omega-6 is 12 mg/g, hence the omega-3 to omega-6 ra-
tio is 29. The placebo used is a mixture of vegetable oils
(virgin cold pressed olive oil, maize oil, palm kernel oil,
medium chain triglycerides), containing no EPA or
DHA, and less than 5 mg/g (0.5%) other omega-3s (pre-
dominantly oleic acid (C18:1n9) and linoleic acid (C18:
2n6)). Both the krill oil and the placebo are provided in
non-distinguishable opaque glycerin softgels. A small
amount of vanilla flavour added to the shell of both ac-
tive and placebo softgels to ensure uniform taste and
smell. All patients will continue usual care by their treat-
ing health practitioners.
Study procedure and time points
Research assistants will first conduct screening over the
telephone. If early checks of study eligibility are
favourable, participants will be booked in for a face-to-
Table 1 Schedule of assessments, KARAOKE study
Visit/week number Screening Baseline (week 0) 4 8 12 16 20 24
Informed consent x
Knee x-ray x
Knee MRI x* x
Clinical measures
Bloods x x x
Clinical examination x
Leg strength x x x
Height and weight x x
Capsules given x x
Capsule count x x
Pressure pain testing (Melbourne/Perth only) x x x
Ultrasound (Perth) x x
Questionnaire measures
Knee VAS x x x x x x x x
Knee WOMAC x x x x x x x
Knee ICOAP x x x x x x x
Patient global evaluation x x x x x x x
Joint replacement surgery x x x
Concomitant medications x x x
Safety (AEs) x x
Hand VAS, back VAS x x x x x x x
AQoL x x x
Patient health questionnaire (PHQ-9) x
Pain at other sites x x x
Treatment guessing x x
painDETECT x
Adverse events As required
Early withdrawal As required
*if otherwise suitable
Laslett et al. Trials           (2020) 21:79 Page 4 of 14
face screening visit to further determine eligibility and
explain what is involved in the study. At the screening
face-to-face visit, patients will complete questionnaires,
have a knee x-ray and MRI, supply a blood sample and
have a clinical assessment by a study doctor to ensure
inclusion criteria are met. The study knee will be defined
as the one with symptomatic OA meeting all inclusion
criteria. If both knees meet these criteria, the study doc-
tor will decide which is the study knee, typically the one
with the highest pain score.
Table 1 outlines the schedule of assessments. After
screening, there will be three study visits (weeks 0, 12
and 24). The same research assistants, who are blinded
to treatment allocation, will measure all clinical vari-
ables, administer questionnaires, monitor compliance
and record adverse events at these visits. Additional
questionnaire mail outs will occur monthly. MRI scans
will occur at screening and week 24; knee x-ray will be
performed at screening; blood samples are taken at
screening, 12 and 24 weeks, and urine samples are taken
at baseline and week 24.
Participants will discontinue involvement in the
study if they need to use drugs that are contraindi-
cated (marine oils, anticoagulants, high dose aspirin,
NSAIDs), they stop taking study medication or the
participant or the site investigators request
discontinuation.
Quality assurance
To ensure high-quality execution of the trial in accord-
ance with the protocol, all trial staff will be trained by
the chief investigators and provided with a standard
protocol book which contains details of standard operat-
ing procedures, trial contacts, visits, measurements,
monitoring and case report forms. Data are collected
using the same forms across sites, these data are checked
by staff in Hobart and any discrepancies are clarified.
Primary outcomes
We have two primary outcomes for this study, assessing
improvements in symptoms and structural progression.
These are change in knee pain assessed by VAS over 24
weeks and change in effusion-synovitis volume assessed
from MRI. All outcomes and time points of assessment
are listed in Table 2.
Other outcome measures
Pain intensity
Knee pain, back pain and hand pain will be assessed
using a 100 mm VAS by asking “on this line, thinking
about your study knee/back/most painful hand, where
would you rate your pain, using the last 7 days as a time
frame” over 4, 8, 12, 16 and 20 (but not 24) weeks.
We will also assess pain using the Western Ontario
and McMasters Universities Osteoarthritis Index
(WOMAC) [42], also over the preceding 7 days. Five
items of the WOMAC pain scale in 100-mm VAS for-
mat [43] will be used to assess pain during walking on a
flat surface, going up and down stairs, at night while in
bed, sitting or lying, and standing upright during the last
7 days. Items will be summed to create a total WOMAC
pain score (range 0–500). Incomplete items will be ad-
dressed according to the WOMAC user guide [44]. If
only one item is missing, the remaining four items will
be averaged and then multiplied by five. The WOMAC
pain score will be considered invalid if more than one
item is missing.
Knee function
Knee function will be assessed using WOMAC [42].
Seventeen items of the WOMAC function scale in 100-
mm VAS format [43] will be used to assess function
during descending stairs, ascending stairs, rising from
sitting, standing, bending to floor/picking up an object,
walking on flat surface, getting in/out of the car, going
shopping, putting on socks/stockings, rising from bed,
taking off socks/stockings, lying in bed, getting in/out of
the bath, sitting, getting on/off the toilet, heavy domestic
duties, and light domestic duties during the last 7 days.
Items will be summed to create a total WOMAC func-
tion score (range 0–1700). If two or fewer items are
missing, the remaining items will be averaged and then
multiplied by 17 [44]. The WOMAC function score will
be considered invalid if more than two items are
missing.
Magnetic resonance imaging outcomes
An MRI scan of the “study” knee will be performed
(screening, week 24). Knees will be imaged in the sagittal
plane on a 1.5 T or 3 T whole-body magnetic resonance
unit using a dedicated knee coil. Sequences will include
T2-weighted fat saturation three-dimensional (3-D) fast
spin echo sequence (effusion-synovitis volume, cartilage
defects, BMLs); T1-weighted fat saturation 3-D gradient-
recalled acquisition sequence (cartilage volume, cartilage
thickness); and T2 mapping (Table 3).
Knee effusion-synovitis Effusion-synovitis is defined as
the presence of intra-articular fluid-equivalent signal
on T2 weighted MRI sequence (Fig. 1). A modified
Whole-Organ Magnetic Resonance Imaging Score
(WORMS) scoring system will be utilised to assess
effusion-synovitis (grade 0 to 3) semi-quantitatively in
four regions of interest (ROI; suprapatellar pouch,
central portion, posterior femoral recess, subpopliteal
recess) in terms of the estimated maximal distention
of the synovial cavity. The greatest score for any of
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the four ROI will be used as maximal effusion of the
knee. The intraclass reliability assessed as weighted κ
in 50 randomly selected images was 0.63–0.75 in dif-
ferent subregions, and the interclass inter-rater reli-
ability was 0.65–0.79 [45].
Effusion-synovitis volume will be measured using a
semi-automated segmentation method according to
the intra-articular fluid-equivalent signal on a section-
by-section basis in each ROI. The final 3-D volume
rendering will be generated using commercial in-
house imaging software. Change in effusion-synovitis
volume is calculated by subtracting baseline values
from follow-up values. The intra-rater reliability was
0.97 in the whole joint (0.98 in suprapatellar pouch
and 0.95 in central portion). The inter-rater reliability
was 0.99 in the whole joint (0.99 in suprapatellar
pouch and 0.93 in central portion). Effusion-synovitis
volume was highly correlated with effusion-synovitis
score (rho 1/4 0.77, P < 0.01 for total; rho 1/4 0.91,
P < 0.01 for suprapatellar pouch; and rho 1/4 0.77,
P < 0.01 for central portion) [46].
Differentiating effusions from synovitis on MR images
requires administration of a contrast agent (gadolinium),
which may cause nephrotoxicity. While this is rare, we
do not consider the benefits of such differentiation be-
tween synovitis and effusion justifies the risk to our
study participants, and hence we have not used it.
Bone marrow lesions Bone marrow lesions (BMLs) will
be defined as an ill-defined hyperintensity area in the
subchondral bone on MRI. BMLs will be assessed on the
sagittal T2 weighted sequences at the medial tibial, med-
ial femoral, lateral tibial, lateral femoral and patella sites
using a modified WORMS scoring system [47]. The
maximum size of each lesion will also be measured using
software cursors applied to the greatest area of the le-
sion, as previously described [48]. We have demon-
strated an intraclass correlation coefficient (ICC) of 0.97
[49] using this method. Total BML size will be calcu-
lated as the sum of every lesion within the medial tibial,
medial femoral, lateral tibial, lateral femoral and patella
sites.
Ultrasound
Knees will be imaged using an Esaote Mylab 70 VXG
ultrasound machine in Perth (Table 4), with scans
undertaken by a single sonographer. Images will be
stored to be re-read to determine intra-reader
reliability).
Synovitis in the supra patella pouch will be defined
as a combination of synovial hypertrophy and effusion
(using Outcome Measures in Rheumatology (OMER-
ACT) definitions [50]) and scored on a 0–3 scale with
grade 0 = no synovitis, grade 1 = minimal distension of
the recess by abnormal internal hypoechoic or an-
echoic (relative to subdermal fat tissue) material,
grade 2 = moderate distension or enlargement of the
recess by abnormal internal hypoechoic or anechoic
(relative to subdermal fat tissue) material with flat or
concave superficial limit, and grade 3 = severe disten-
sion or enlargement of the recess by abnormal in-
ternal hypoechoic or anechoic (relative to subdermal
fat tissue) material with bulging superficial limit.
Depth of effusion (mm) will be measured only in the
suprapatellar pouch (SPP), from a still midline longi-
tudinal image, measuring the maximal effusion depth
in this plane.
In the SPP, medial parapatellar region and lateral
parapatellar region, synovial hypertrophy, effusion and
power doppler signal (defined using OMERACT
Table 2 Primary and secondary outcomes
Outcome Time points
Primary outcomes
Knee pain: VAS score 24 weeks
Knee effusion-synovitis: maximal area, volume, or-
dinal measures (MRI)
24 weeks
Secondary outcomes
BML: maximal area 24 weeks
Effusion volume (ultrasound)γ 24 weeks
Knee pain: VAS score 4, 8, 12, 16, 20
weeks
Knee pain: total WOMAC pain, weight bearing and
non-weight bearing pain
all time points
Hand and back pain (VAS) All time points
Knee function All time points
OMERACT–OARSI responder criteria [41] All time points
hs-CRP 12 and 24
weeks
Blood lipids 12 and 24
weeks
Blood glucose 12 and 24
weeks
Leg strength 12 and 24
weeks
Analgesic use All time points
Quality of life (AQoL-6D) 12 and 24
weeks
Pressure pain threshold testing on study knee¥ 24 weeks
Adverse events 12 and 24
weeks
Medication persistence 12 and 24
weeks
Cost data: hospitalisation, medication use, joint
replacement
γ Perth only
¥ Melbourne and Perth ONLY
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definitions [50]) will be scored as absent (0) or
present (1).
Pressure pain threshold testing
Pressure pain threshold (PPT) testing will be conducted
using a pressure algometer (FDN200, Wagner Instru-
ments, USA) with a probe area of 1 cm2, which exerts
pressures of up to 200 N/cm2/2000 kPa. The PPT is de-
termined using an ascending stimulus intensity (slowly
increasing ramps of 50 kPa/s (~ 0.5 kg/cm2s) applied
bilaterally over the three test sites: the affected joint
(knee, assessed over the tibial below the medial joint
line), an unaffected joint (ipsilateral proximal radioul-
nar joint), and over the thenar eminence. The study
participant is asked to notify the examiner as soon as
the sensation becomes painful, and the pressure
exerted recorded. The PPT is determined by the
mean of the threshold from a series of three stimulus
intensities each applied as a slowly increasing ramp of
50 kPa/s [51].
OMERACT–OARSI responder criteria
Response to krill oil will be assessed using the OMER-
ACT–Osteoarthritis Society International (OARSI) set of
response criteria [41]. Participants will be classed as
responding if they have high improvement in pain
(using the VAS) or function (using WOMAC function
scale) of ≥ 50% and absolute change ≥ 20; or if they
have positive relative (≥ 20%) or absolute (≥ 10)
change in two out of three of pain, function or pa-
tient’s global assessment.
Lower limb muscle strength
Lower limb muscle strength is a key correlate of pain
and typically increases when pain reduces [52]. We will
assess lower limb leg strength in both legs simultan-
eously, using a dynamometer (TTM Muscular Meter,
Tokyo, Japan) as previously described [21]. This is done
in duplicate and the mean of the two estimates is used.
The muscles measured in this technique are mainly the
quadriceps and hip flexors. The previously published re-
peatability estimate (Cronbach’s α) for this method is
0.91 [53].
Measure of intermittent and constant osteoarthritis pain
Intermittent and constant osteoarthritis pain (ICOAP)
is a multidimensional OA-specific measure designed
to comprehensively evaluate the pain experience in
people with hip or knee OA. This includes pain in-
tensity, frequency, and impact on mood, sleep and
quality of life, independent of the effect of pain on
physical function [54], over the past 7 days. It con-
tains 11 items in two domains with two supplemen-
tary items on intermittent pain predictability, and
uses rating scales with five categories of response,
e.g., “not at all,” “mildly,” “moderately,” “severely,”
and “extremely” [54]. Each ICOAP item is scored
from 0 to 4; missing data are dealt with according to
rules in the user guide [55]. Scores are produced for
each subscale separately by summing subscale scores
for each item and then normalising each score from
0 (no pain) to 100 (extreme pain). The ICOAP is re-
liable (Cronbach’s α 0.93, ICC 0.85 [54]) and valid
[54].
Quality of life
Quality of life will be assessed using the Assessment of
Quality of Life (AQoL-6D) questionnaire, which assesses
six separately scored dimensions (Independent Living,
Relationships, Mental Health, Coping, Pain and Senses),
Fig. 1 Example of changes in effusion-synovitis area (cm2). Effusion-synovitis size decreased from baseline to follow-up 2.6 years later (a, b).
Effusion/synovitis are present in both the suprapatellar pouch and central portion. Overall, effusion size is smaller at follow-up MRI
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each with variable item numbers and response levels
[56]. The AQoL-6D has good psychometric properties
[57]. Utility scores will be calculated based on
methods published on the AQoL website [56] with a
range 0–1 where 0 indicates the worst health state
and 1 the best.
Blood samples
Fasting blood samples will be obtained from study par-
ticipants at screening, 12 and 24 weeks. Samples will be
analysed for fasting glucose, lipids (total, HDL and LDL)
and hsCRP. The blood will be either tested fresh or
stored at − 80 °C.
Other assessments
Radiographs
A standing anteroposterior semiflexed radiograph of the
‘study’ knee will be performed at screening. X-rays will
be scored for joint space narrowing and osteophytes on
a four point scale (0–3) using the OARSI atlas [39]. In
our hands this method has very high reproducibility with
an ICC of 0.98 for joint space narrowing and 0.99 for
osteophytes [58].
Anthropometry
These include height (stadiometer) and weight (elec-
tronic scales) and body mass index (BMI) (weight/
height2) measured at weeks 0, 12 and 24.
painDETECT
Neuropathic pain will be assessed by the painDETECT
questionnaire (− 1 to 38) at screening to provide infor-
mation on level of nociceptive and/or neuropathic con-
tributions to pain. A painDETECT score < 12 is defined
as unlikely neuropathic pain, and 13–18 as possible
neuropathic pain [59].
Concomitant medication
Use of pain medicines will be recorded by questionnaire
at all visits. Participants will be asked to keep medica-
tions as stable as possible (including NSAIDs) and use
paracetamol as rescue medication. Use of fish and krill
oil during the trial will not be permitted, and use must
cease 2 weeks prior to randomisation. Participants who
commence anti-coagulant therapy will be withdrawn
from the trial. We will assess analgesic use from the
medication data.
Treatment guessing and adherence
Study participants will be asked what treatment they
think they received at the 12- and 24-week assessments
with the following options: krill oil, placebo, or not sure.
Adherence to treatment will also be assessed at the
12- and 24-week assessments by standard pill count
methods [60].
Safety assessment
Adverse events will be monitored throughout the study.
Standard safety and efficacy monitoring will be per-
formed through regular face-to-face visits and phone
calls between visits. The patients are requested to report
any adverse events to the research staff spontaneously.
Details of the adverse event and its relationship with
study intervention will be recorded and reported to the
local Human Research Ethics Committees in accordance
with the requirements of individual committees.
Sample size calculations
Using data from another trial conducted in our centre
[52], assuming 10-mm difference between krill oil and
placebo on the VAS pain scale (reduction in VAS pain
scores in the placebo group by − 15.5 ± 25.5 mm over 12
weeks) and using assumptions of 90% power and 5%
probability of type 1 error (alpha = 0.05), we will need
234 participants. Adjusting for 10% loss to follow-up, we
need 260 participants (130 in each arm). Based on data
on effusion-synovitis volume in our vitamin D RCT for
knee OA, there was 13.7 ml (SD = 10.7) in the placebo
group and 13.6 ml (8.1) in the active group (in those
with effusion-synovitis at enrolment, i.e., 60%) at base-
line [61]. With 234 subjects we will have 90% power to
detect a difference of 4.5 ml. It is likely we will see at
least a reduction of this amount with a treatment that
effectively targets inflammation. What level reflects clin-
ical significance is uncertain but this level is approxi-
mately 2.5 times the change that could be expected with
measurement error. Furthermore, modelled data from
our long-term Tasmanian cohort demonstrates that a re-
duction in effusion-synovitis size by 4.5 ml will decrease
the need for joint replacement by 30% over 13 years (un-
published data).
Statistical analysis
The primary analyses will be intention-to-treat analyses
of primary and secondary outcomes. Per protocol ana-
lyses will be performed as the secondary analyses.
Changes in knee pain, knee effusion-synovitis size and
any other outcomes which were collected using a linear
scale will be analysed using a linear mixed model with
treatment, month and their interaction (treatment ×
month) as covariates, as well as outcome measured at
baseline and the baseline interaction with month. Inci-
dence of adverse events will be assessed using log bino-
mial regression. Correlated data within trial centres and
the repeated measures will be addressed using trial
centre and patient identification as random intercepts.
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Month will be treated as random effect to allow different
treatment effects among patients over time. The sensitiv-
ity of models to the structure for the random effects and
covariance structures will be assessed using likelihood
ratio tests. Change in outcome measures within each
group and differences in changes between groups from
baseline to follow-up will be calculated using linear com-
binations of the estimated coefficients. If there are base-
line imbalances in covariates between treatment groups,
we will consider adjusting for them based on whether
we regard the imbalance as clinically significant. Missing
data caused by loss to follow-up and non-responses will
be addressed by adding variables that have complete
data at baseline and can explain missingness to the re-
gression models.
Secondary analysis for missing data will be performed
in people with full medication adherence (e.g., > 80% of
softgels) and using imputation. Baseline variables with
complete data will be used for data imputation assuming
missing at random.
Subgroup analyses will be performed to examine which
subgroups may respond better to treatment. These will in-
clude effusion size, radiographic knee OA, co-pathology
present on MRI, pain characteristics, levels of inflamma-
tory markers and serum lipid measures. Statistical signifi-
cance will be set as a two-sided P value < 0.05.
Data integrity and management
Data will be recorded using case report forms and
processed centrally at the Menzies Institute for Med-
ical Research, University of Tasmania. The hard cop-
ies of case report forms will be stored in a locked
area at each study site with secured and restricted ac-
cess. The electronic data will be stored on password-
protected servers with restricted access. All data col-
lected will be kept strictly confidential. Daily backups
of all electronic data will occur to minimise any risk
of lost data. Data transfer will be encrypted with all
data de-identified. Only members of the research
team who need to contact study patients, enter data
or perform data quality control will have access to
patient information.
After study completion, paper copies of data will be
archived in secure storage. Identifiers will not be re-
moved in case follow-up of study patients is necessary;
however, electronic data will continue to be kept in a se-
cure electronic database. This will remain password pro-
tected and with access given only to the study
investigators unless otherwise authorised by the study
team.
Withdrawal
If patients withdraw from the study before 6 months of
follow-up, the reason and date will be recorded. An early
MRI will be considered for participants who can not
make the final visit.
Roles and responsibilities and monitoring
The University of Tasmania (as the trial sponsor) and
the principal investigators are responsible for all aspects
of the trial, including design, conduct and oversight. The
principal investigators will monitor the conduct and pro-
gress of the project at each site. The trial coordinator
will visit each study site to make sure that all trial proce-
dures are compliant with the trial protocol. The princi-
pal investigators and the research team will have regular
teleconferences to ensure efficient study execution and
ongoing monitoring of the study progress, with sum-
mary documents circulated after each meeting. Krill oil
has a good safety profile [31] and is available over-the-
counter, so we do not plan to use a data safety monitor-
ing board. The trial is also being monitored at each site
by a practicing rheumatologist.
Dissemination plans
The results of this study will be presented at conferences
and published in scientific journals. Any notes or publi-
cations arising from our research will be de-identified.
Only aggregate statistical results will be presented.
The outcomes of the project will be disseminated to
study patients using non-technical language. Dissemin-
ation of the overall study findings to the patients will
occur in a de-identified manner and be based on the en-
tire study population. The scientific paper will be avail-
able for dissemination to study participants.
Discussion
We propose a multicentre, randomised, double blind
placebo-controlled trial to determine whether krill oil 2
g/day improves knee pain and reduces size of knee
effusion-synovitis compared to placebo in people with
clinical knee OA, significant knee pain and knee
effusion-synovitis. If krill oil proves effective, it will offer
a novel therapeutic approach to reduce or slow progres-
sion of knee OA.
Krill oil is theorised to have an effect via both anti-
inflammatory and anti-oxidative mechanisms. Oxidative
stress and inflammation have important roles in OA
pathogenesis and krill oil therapy may be beneficial in
treating OA. Krill oil (300 mg/day) reduced inflamma-
tion (as measured by CRP) by 30% in 30 days vs 25% in-
crease in patients receiving placebo [34]. This may have
important clinical implications, with low level inflamma-
tion associated with increased loss of tibial cartilage vol-
ume (β = − 1.18% per annum per quartile of IL-6) [62]).
Accordingly, trials are starting to use MRI-assessed effu-
sion/synovitis as a treatment target. In a trial using low
dose oral prednisolone for painful hand OA, MRI-
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assessed effusion-synovitis was associated with pain
cross-sectionally, but not hand pain as assessed by VAS;
however, effusions did not change over time with treat-
ment or predict response to treatment [63].
Effusion and synovitis can also be assessed using ultra-
sound; such effusions predict knee replacements inde-
pendent of severity of radiographic damage and pain
[20]. Presence of ultrasound-detected knee effusions has
been used to select people who might respond well to
oral methotrexate, which demonstrated efficacy in an
open-label trial, albeit without a control group [64].
However, the reproducibility of ultrasound is largely
dependent on the operator and ultrasound is not yet
well utilised in clinical trials of knee OA. This study will
enable comparisons of MRI vs ultrasound indices in
assessing change in effusion volume and provide evi-
dence of which imaging modality is of most use in this
context.
In summary, knee OA is a major but poorly under-
stood public health problem with no pharmacologic
therapies that affect disease progression. Two small trials
[34, 35] suggest that krill oil will improve knee pain and
may reduce systemic inflammation in people with OA. If
krill oil can reduce knee pain and effusion size in knee
OA, study findings will be readily translated into clinical
practice as krill oil is already popular and available over
the counter despite limited evidence of efficacy.
Trial status
Trial status: Completed recruiting.
Protocol version number and date: Scientific protocol
V2 (08 April 2016), Standard operating procedures: V4
(Hobart site, 13 November 2017), V3 (Adelaide site, 23
August 2016).
Date recruitment began: 06 December 2016, recruit-
ment complete July 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3915-1.
Additional file 1. SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents.
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